{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:04:36Z","timestamp":1777860276384,"version":"3.51.4"},"reference-count":75,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JRS"],"published-print":{"date-parts":[[2021,1,25]]},"abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) is a viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) presenting with pulmonary and extra-pulmonary manifestations. The first case was reported in Wuhan, China in December 2019 and it has rapidly progressed to the form of a pandemic. The presentation is mild in about 80 percent of the cases but the disease can also progress to a severe form of respiratory illness leading to acute respiratory distress syndrome (ARDS) and sometimes multi-organ failure, especially in people with other co-morbidities. Pregnant women also appear to be at a greater risk of acquiring a severe infection due to physiological changes during pregnancy. Many drugs with in vitro activity against the virus or an immunomodulatory effect have been considered for repurposing or have been tried as off-label drugs. The safety data regarding the use of newly approved or off-label or investigational drugs in pregnant women is limited and this poses a great challenge for clinicians. Therefore, it is important to know the utility and safety of the medications to avoid untoward adverse effects on pregnant women and fetuses. In this review, we aim to provide an overview of the approved, off-label, unlicensed, new and some promising pharmacological options for their use in the treatment of COVID-19 and the safety profile in pregnancy in an Indian scenario.<\/jats:p>","DOI":"10.3233\/jrs-200060","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T11:06:18Z","timestamp":1609239978000},"page":"3-17","source":"Crossref","is-referenced-by-count":5,"title":["Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective"],"prefix":"10.1177","volume":"32","author":[{"given":"Kavita","family":"Manchanda","sequence":"first","affiliation":[{"name":", Milann Fertility Centre, , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasbir","family":"Singh","sequence":"additional","affiliation":[{"name":"Associate Professor, , Government Medical College and Rajindra Hospital, , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjeev","family":"Bhagat","sequence":"additional","affiliation":[{"name":", , Government Medical College and Hospital, , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilmjot Kaur","family":"Tiwana","sequence":"additional","affiliation":[{"name":", Government Medical College and Rajindra Hospital, , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harmanjit","family":"Singh","sequence":"additional","affiliation":[{"name":", , Government Medical College and Hospital, , India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JRS-200060_ref2","volume-title":"StatPearls [Internet]","author":"Cascella","year":"2020"},{"issue":"4","key":"10.3233\/JRS-200060_ref3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/uog.22006","article-title":"Novel coronavirus infection and pregnancy","volume":"55","author":"Yang","year":"2020","journal-title":"Ultrasound in Obstetrics and Gynecology"},{"issue":"1","key":"10.3233\/JRS-200060_ref4","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ajog.2003.11.019","article-title":"Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome","volume":"191","author":"Wong","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.3233\/JRS-200060_ref6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.15585\/mmwr.mm6925a1","article-title":"Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status- United States, January 22-June 7, 2020","volume":"69","author":"Ellington","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"15","key":"10.3233\/JRS-200060_ref7","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1001\/jama.2010.479","article-title":"Pandemic H1N1 influenza in pregnancy working group. Pandemic 2009 influenza A (H1N1) virus illness among pregnant women in the United States","volume":"303","author":"Siston","year":"2010","journal-title":"JAMA"},{"issue":"3","key":"10.3233\/JRS-200060_ref8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jmii.2018.04.005","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV) infection during pregnancy: Report of two cases & review of the literature","volume":"52","author":"Alfaraj","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"10.3233\/JRS-200060_ref9","doi-asserted-by":"crossref","first-page":"111.e1","DOI":"10.1016\/j.ajog.2020.04.014","article-title":"Coronavirus disease 2019 in pregnant women: A report based on 116 cases","volume":"223","author":"Yan","year":"2020","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"1","key":"10.3233\/JRS-200060_ref10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ajcp\/aqaa089","article-title":"Placental pathology in COVID-19","volume":"154","author":"Shane","year":"2020","journal-title":"Am J Clin Path"},{"issue":"2","key":"10.3233\/JRS-200060_ref11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ajcp\/aqaa101","article-title":"Placental pathology in Covid-19","volume":"154","author":"Baergen","year":"2020","journal-title":"American Journal of Clinical Pathology"},{"issue":"1","key":"10.3233\/JRS-200060_ref14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/AOG.0000000000003924","article-title":"Protection by exclusion: another missed opportunity to include pregnant women in research during the coronavirus disease 2019 (COVID-19) pandemic","volume":"136","author":"Costantine","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.3233\/JRS-200060_ref15","first-page":"1","article-title":"Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening","volume":"23","author":"Zhao","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.3233\/JRS-200060_ref16","doi-asserted-by":"crossref","unstructured":"Savarino A, Boelaert RJ, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: An old drug against today\u2019s diseases. 2003;3(11):722\u20137.","DOI":"10.1016\/S1473-3099(03)00806-5"},{"issue":"5","key":"10.3233\/JRS-200060_ref17","doi-asserted-by":"publisher","first-page":"105938","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.3233\/JRS-200060_ref18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3785\/j.issn.1008-9292.2020.03.03","article-title":"A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19","volume":"49","author":"Chen","year":"2020","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"issue":"1","key":"10.3233\/JRS-200060_ref19","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"6","key":"10.3233\/JRS-200060_ref21","doi-asserted-by":"publisher","first-page":"e008688","DOI":"10.1161\/CIRCEP.120.008688","article-title":"Use of chloroquine and hydroxychloroquine in COVID-19 and cardiovascular implications: Understanding safety discrepancies to improve interpretation and design of clinical trials","volume":"13","author":"Oren","year":"2020","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"8","key":"10.3233\/JRS-200060_ref22","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.mayocp.2020.05.005","article-title":"Acute QT interval modifications during hydroxychloroquine-azithromycin treatment in the context of COVID-19 infection","volume":"95","author":"Voisin","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.3233\/JRS-200060_ref23","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1002\/art.11304","article-title":"Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty-three cases compared with a control group","volume":"48","author":"Costedoat-Chalumeau","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.3233\/JRS-200060_ref24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa2016638","article-title":"A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19","volume":"383","author":"Boulware","year":"2020","journal-title":"N Engl J Med"},{"key":"10.3233\/JRS-200060_ref25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ijid.2020.06.099","article-title":"Henry Ford COVID-19 task force. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19","author":"Arshad","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"24","key":"10.3233\/JRS-200060_ref26","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State","volume":"323","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"issue":"25","key":"10.3233\/JRS-200060_ref27","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.3233\/JRS-200060_ref30","doi-asserted-by":"publisher","first-page":"43395","DOI":"10.1038\/srep43395","article-title":"GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci Rep"},{"issue":"396","key":"10.3233\/JRS-200060_ref31","doi-asserted-by":"publisher","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.3233\/JRS-200060_ref32","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.3233\/JRS-200060_ref33","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - Preliminary report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.3233\/JRS-200060_ref34","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe covid-19: A randomized, double-blind, placebo-controlled multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"The Lancet"},{"key":"10.3233\/JRS-200060_ref35","doi-asserted-by":"publisher","first-page":"ciaa883","DOI":"10.1093\/cid\/ciaa883","article-title":"Drug-induced liver injury in a COVID-19 patient: Potential interaction of remdesivir with P-glycoprotein inhibitors [published online ahead of print, 2020 Jun 28]","author":"Leegwater","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.3233\/JRS-200060_ref36","unstructured":"World Health Organization; 2020 Feb. Guidelines for the management of pregnant and breast-feeding women in context of Ebola virus disease- Evidence-to-decision tables. ISBN 978-92-4-000138-1."},{"key":"10.3233\/JRS-200060_ref40","doi-asserted-by":"publisher","first-page":"101710","DOI":"10.1016\/j.tmaid.2020.101710","article-title":"Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence","volume":"35","author":"Khambholja","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"10.3233\/JRS-200060_ref42","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.17.20037432"},{"issue":"10","key":"10.3233\/JRS-200060_ref43","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID19: An open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"},{"issue":"5","key":"10.3233\/JRS-200060_ref45","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2147\/tcrm.s3285","article-title":"Lopinavir\/ritonavir in the treatment of HIV-1 infection: A review","volume":"4","author":"Chandwani","year":"2008","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"10.3233\/JRS-200060_ref46","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4103\/ijmr.IJMR_502_20","article-title":"Lopinavir\/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use","volume":"151","author":"Bhatnagar","year":"2020","journal-title":"Indian Journal of Medical Research"},{"issue":"3","key":"10.3233\/JRS-200060_ref47","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/2048872620922784","article-title":"Cardiac safety of off-label COVID-19 drug therapy: A review and proposed monitoring protocol","volume":"9","author":"Naksuk","year":"2020","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.3233\/JRS-200060_ref48","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2020.224"},{"key":"10.3233\/JRS-200060_ref49","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\/ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.3233\/JRS-200060_ref50","first-page":"38","article-title":"Safety and efficacy of lopinavir\/ritonavir during pregnancy: A systematic review","volume":"15","author":"Pasley","year":"2013","journal-title":"AIDS Rev"},{"issue":"1","key":"10.3233\/JRS-200060_ref51","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jamapediatrics.2014.1889","article-title":"Congenital anomalies and in-utero anti-retroviral exposure in human immunodeficiency virus-exposed uninfected infants","volume":"169","author":"Williams","year":"2015","journal-title":"JAMA Pediatr"},{"key":"10.3233\/JRS-200060_ref54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"issue":"3","key":"10.3233\/JRS-200060_ref55","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.23812\/20-EDITORIAL_1-5","article-title":"Dexamethasone for COVID-19? Not so fast","volume":"34","author":"Theoharides","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"issue":"34","key":"10.3233\/JRS-200060_ref56","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.2174\/1381612820666140205144534","article-title":"Dexamethasone use during pregnancy: Potential adverse effects on embryonic skeletogenesis","volume":"20","author":"Cheng","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.3233\/JRS-200060_ref57","first-page":"m3305","article-title":"Include pregnant women in research\u2014particularly covid-19 research","volume":"370","author":"Marian","year":"2020","journal-title":"BMJ"},{"issue":"4","key":"10.3233\/JRS-200060_ref58","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40290-020-00342-z","article-title":"IL-6 inhibitors in the treatment of serious COVID-19: A promising therapy?","volume":"34","author":"Atal","year":"2020","journal-title":"Pharmaceut Med"},{"key":"10.3233\/JRS-200060_ref59","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.01.20047381"},{"issue":"11","key":"10.3233\/JRS-200060_ref60","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1002\/jmv.26038","article-title":"Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review","volume":"92","author":"Antwi-Amoabeng","year":"2020","journal-title":"J Med Virol"},{"issue":"8","key":"10.3233\/JRS-200060_ref61","doi-asserted-by":"publisher","first-page":"E474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe covid-19: A retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"The Lancet Rheumatology"},{"issue":"5","key":"10.3233\/JRS-200060_ref64","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3109\/14397595.2016.1147405","article-title":"Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan","volume":"26","author":"Nakajima","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"8","key":"10.3233\/JRS-200060_ref65","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/rheumatology\/kez100","article-title":"Tocilizumab during pregnancy and lactation: Drugs levels in maternal serum, cord blood, breast milk and infant serum","volume":"58","author":"Saito","year":"2019","journal-title":"Rheumatology"},{"issue":"1","key":"10.3233\/JRS-200060_ref67","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/13102818.2020.1775118","article-title":"Ivermectin as a potential covid-19 treatment from the pharmacokinetic point of view: anti-viral are not likely attainable with known dosing regimens","volume":"34","author":"Momekov","year":"2020","journal-title":"Journal Biotechnology and Biotechnological Equipment"},{"key":"10.3233\/JRS-200060_ref68","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41429-020-0336-z","article-title":"Ivermectin: A systematic review from antiviral effects to COVID-19 complementary regimen","volume":"73","author":"Heidary","year":"2020","journal-title":"The Journal of Antibiotics"},{"key":"10.3233\/JRS-200060_ref69","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"issue":"4","key":"10.3233\/JRS-200060_ref70","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.bjid.2020.06.002","article-title":"Ivermectin: Potential candidate for the treatment of Covid 19","author":"Gupta","year":"2020","journal-title":"Braz J Infect Dis"},{"issue":"12","key":"10.3233\/JRS-200060_ref71","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1046\/j.1360-2276.2003.01142.x","article-title":"Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis","volume":"8","author":"Gyapong","year":"2003","journal-title":"Trop Med Int Health"},{"key":"10.3233\/JRS-200060_ref72","first-page":"89","volume-title":"Toxicology","author":"Lankas","year":"1989"},{"key":"10.3233\/JRS-200060_ref73","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/S2214-109X(19)30453-X","article-title":"Safety of oral ivermectin during pregnancy: A systematic review and meta-analysis","volume":"8","author":"Nicolas","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"suppl 1","key":"10.3233\/JRS-200060_ref74","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1475-2883-2-S1-S8","article-title":"Ivermectin: Does P-glycoprotein play a role in neurotoxicity?","volume":"2","author":"Edwards","year":"2003","journal-title":"Filaria J"},{"issue":"4","key":"10.3233\/JRS-200060_ref75","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/jac\/dkz524","article-title":"Safety of high-dose ivermectin: A systematic review and meta-analysis","volume":"75","author":"Navarro","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.3233\/JRS-200060_ref77","doi-asserted-by":"publisher","first-page":"106053","DOI":"10.1016\/j.ijantimicag.2020.106053","article-title":"Macrolides and viral infections: focus on azithromycin in COVID-19 pathology","volume":"56","author":"Pani","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.3233\/JRS-200060_ref78","doi-asserted-by":"crossref","first-page":"101738","DOI":"10.1016\/j.tmaid.2020.101738","article-title":"Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille","volume":"35","author":"Million","year":"2020","journal-title":"France\u00a0Travel Med Infect Dis"},{"issue":"4","key":"10.3233\/JRS-200060_ref79","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"Molina","year":"2020","journal-title":"Med Mal Infect"},{"key":"10.3233\/JRS-200060_ref80","doi-asserted-by":"crossref","unstructured":"Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. 2020, 12203: 1\u201310.","DOI":"10.1001\/jama.2020.8630"},{"issue":"11","key":"10.3233\/JRS-200060_ref82","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/jdv.14345","article-title":"Doxycycline as an anti-inflammatory agent: Updates in dermatology","volume":"31","author":"Henehan","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.3233\/JRS-200060_ref83","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1358\/mf.1998.20.8.487489","article-title":"Antimurine retroviral effect of doxycycline","volume":"20","author":"Sturtz","year":"1998","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"4","key":"10.3233\/JRS-200060_ref84","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00705-013-1880-7","article-title":"Inhibitory effect of doxycycline against dengue virus replication in vitro","volume":"159","author":"Rothan","year":"2014","journal-title":"Arch Virol"},{"key":"10.3233\/JRS-200060_ref85","doi-asserted-by":"crossref","first-page":"e00864","DOI":"10.1016\/j.idcr.2020.e00864","article-title":"Doxycycline as a potential partner of COVID-19 therapies","volume":"21","author":"Male","year":"2020","journal-title":"IDCases"},{"key":"10.3233\/JRS-200060_ref86","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-38896\/v1"},{"issue":"3","key":"10.3233\/JRS-200060_ref88","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1517\/14740338.2016.1133584","article-title":"Revisiting doxycycline in pregnancy and early childhood- time to rebuild its reputation?","volume":"15","author":"Cross","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"10.3233\/JRS-200060_ref90","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1002\/jmv.25961","article-title":"Convalescent plasma transfusion for the treatment of COVID-19: Systematic review","volume":"92","author":"Rajendran","year":"2020","journal-title":"J Med Virol"},{"issue":"1","key":"10.3233\/JRS-200060_ref92","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for Ebola virus disease in Guinea","volume":"374","author":"Griensven","year":"2016","journal-title":"N Engl J Med"},{"key":"10.3233\/JRS-200060_ref93","doi-asserted-by":"crossref","first-page":"e00221","DOI":"10.1016\/j.crwh.2020.e00221","article-title":"The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report","volume":"27","author":"Anderson","year":"2020","journal-title":"Case Reports in Women\u2019s Health"},{"issue":"9","key":"10.3233\/JRS-200060_ref95","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/14712598.2020.1798399","article-title":"Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications","volume":"20","author":"Loganathan","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"10.3233\/JRS-200060_ref96","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3390\/molecules25071577","article-title":"Antioxidant potential of antiviral drug umifenovir","volume":"25","author":"Proskurnina","year":"2020","journal-title":"Molecules"},{"key":"10.3233\/JRS-200060_ref97","first-page":"9","article-title":"Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in cell cultures","volume":"53","author":"Khamitov","year":"2008","journal-title":"Vopr Virusol"},{"issue":"7","key":"10.3233\/JRS-200060_ref98","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cmi.2020.04.026","article-title":"Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study","volume":"26","author":"Lian","year":"2020","journal-title":"Clin Microbiol Infect"}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JRS-200060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:45:18Z","timestamp":1777509918000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JRS-200060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":75,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jrs-200060","relation":{},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,25]]}}}